Rexulti, the first drug to relieve Alzheimer's emotions - TimesKuwait

The US Food and Drug Administration (FDA) has granted fast-track approval of the first drug aimed at relieving the emotions associated with Alzheimer’s disease. The FDA published, on its official website, a statement confirming the approval of Otsuka Pharmaceutical Company and Lundbeck, producers of oral Rexulti tablets to relieve the emotions associated with Alzheimer’s disease, […]

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

First-Ever Drug for Alzheimer's Agitation, Brexpiprazole, Nears Finish Line

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

Lundbeck, Otsuka drug cut agitation in Alzheimer's patients

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

This Antipsychotic Drug Can Now Be Used to Treat Agitation in Alzheimer's Patients

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease

Positive Data for First and Only Treatment Approved for Agitation in Alzheimer Dementia

FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients

FDA Approves First-Ever Drug for Agitation Associated with Alzheimer's Dementia

Positive Data for First and Only Treatment Approved for Agitation in Alzheimer Dementia

Fake smiles star in Otsuka and Lundbeck's DTC push for Rexulti in depression